Orphalan Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Private

  • Employees
  • 137

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 2

Orphalan General Information

Description

Developer of treatments for rare diseases intended to improve the lives of patients. The company uses a global network of experts, including scientists, academic institutions, and companies, to identify, develop, and provide access to treatments for patients with rare diseases to make a positive difference, enabling healthcare workers to provide treatments and services that work for patients.

Contact Information

Formerly Known As
GMP-Orphan
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 226 Boulevard Voltaire
  • 75011 Paris
  • France
+33 01
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Corporate Office
  • 226 Boulevard Voltaire
  • 75011 Paris
  • France
+33 01

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Orphalan Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Secondary Transaction - Private 01-Dec-2024 Completed Generating Revenue
3. Debt - General 02-Jan-2019 Completed Generating Revenue
2. Early Stage VC (Series A) 01-Jan-2015 Completed Generating Revenue
1. Accelerator/Incubator 01-Jan-2011 Completed Startup
To view Orphalan’s complete valuation and funding history, request access »

Orphalan Patents

Orphalan Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260130867-A1 Formulation Pending 08-Nov-2024
EP-4777083-A1 Formulation comprising triethylenetetramine tetrahydrochloride Pending 08-Nov-2024
ES-3082744-T1 Formulation comprising triethylenetetramine tetrahydrochloride Pending 08-Nov-2024
WO-2026099431-A1 Formulation comprising triethylenetetramine tetrahydrochloride Pending 08-Nov-2024
EP-4329738-A1 Non-ceruloplasmin bound copper level monitoring Pending 26-Apr-2021 A61K31/132
To view Orphalan’s complete patent history, request access »

Orphalan Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Orphalan Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Advent Life Sciences Venture Capital Minority
La Synapse Accelerator/Incubator
To view Orphalan’s complete investors history, request access »

Orphalan Acquisitions (1)

Orphalan’s most recent deal was a Merger/Acquisition with Orphelia Pharma.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Orphelia Pharma Merger/Acquisition Pharmaceuticals
To view Orphalan’s complete acquisitions history, request access »

Orphalan Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Orphelia Pharma Paris, France 2007

Orphalan FAQs

  • When was Orphalan founded?

    Orphalan was founded in 2011.

  • Where is Orphalan headquartered?

    Orphalan is headquartered in Paris, France.

  • What is the size of Orphalan?

    Orphalan has 137 total employees.

  • What industry is Orphalan in?

    Orphalan’s primary industry is Biotechnology.

  • Is Orphalan a private or public company?

    Orphalan is a Private company.

  • What is Orphalan’s current revenue?

    The current revenue for Orphalan is .

  • Who are Orphalan’s investors?

    Advent Life Sciences and La Synapse have invested in Orphalan.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process